Skip to content

Dermal Wound Closure Using Silkam®

Assessment of Performance of Silkam® Suture Material for Skin Closure - a Prospective, Single Center, Single Arm, Observational Study in Daily Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05225714
Acronym
DERMASILK
Enrollment
161
Registered
2022-02-04
Start date
2022-07-21
Completion date
2025-06-25
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contusions, Incision, Laceration

Brief summary

Assessment of performance of Silkam® suture material for skin closure. A prospective, single center, single arm, observational study in daily practice.

Detailed description

The prospective, monocentric, single-arm, observational Post Market Clinical Follow-Up (PMCF) study is done to continue to evaluate the safety and performance of Silkam® suture material for skin closure under clinical routine. Safety and effectiveness parameters commonly used in skin closure are to be used to evaluate the performance of the suture material. The aim of this Non Interventional Study is to collect systematically and proactively different clinical parameters regarding safety, effectiveness and performance of Silkam® suture material under the daily routine clinical practice when used for skin closure as intended.

Interventions

None listed

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
B.Braun Surgical SA
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Adult and paediatric patients undergoing skin closure using Silkam® as suture material. * Written informed consent regarding the data collection for the PMCF study.

Exclusion criteria

* Pregnancy * Visible dirty wounds * Patients taking medication that might affect wound healing * Patients with hypersensitivity or allergy to the suture material

Design outcomes

Primary

MeasureTime frameDescription
Surgical Site Infection Rateat suture removal approx. 10 ± 5 days postoperativeA surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only (A1). Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material. (A2)

Secondary

MeasureTime frameDescription
Individual A1 Surgical Site Infection Rateat suture removal approx. 10 ± 5 days postoperativeA surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only (A1).
Individual A2 Surgical Site Infection Rateat suture removal approx. 10 ± 5 days postoperativeA surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be more serious and can involve tissues under the skin, organs, or implanted material. (A2)
Adverse Event Rateat suture removal approx. 10 ± 5 days postoperativefrequency of wound dehiscence, hypertrophic scar, keloid scar, inflammation, tissue reaction, seroma, abscess formation, hematoma, granuloma, bleeding, necrosis, skin stripping or irritation.
Cosmetic Outcomeat suture removal approx. 10 ± 5 days postoperativeOverall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS). Cosmetic result and the scar will be evaluated by the patient and the physician. Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each. The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each. The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum).
Pain: Visual Analogue Scale (VAS)at suture removal approx. 10 ± 5 days postoperativeThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".
Satisfaction of the patient: Visual Analogue Scale (VAS)at suture removal approx. 10 ± 5 days postoperativeThis parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "very poor" and "100" at the opposite end representing "excellent".
Assessment of the handling of the suture materialintraoperativeAssessment of the handling of the suture material intra-operatively using a questionnaire including different dimensions (knot security, tensile strength, knot run down, tissue drag, pliability) with 5 evaluation levels (excellent, very good, good, satisfied, poor).

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 21, 2026